Essential thrombocythemia: Past and present

Internal and Emergency Medicine

Volumn 4, Issue 5, 2009, Pages 381-388

  Fabris, Fabrizio ^a   Randi, Maria Luigia ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

JAK2; Myeloproliferative disorders; Platelets; Thrombocythemia

Indexed keywords

JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

AGED; FEMALE; HISTORY; HUMAN; MALE; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE; THROMBOCYTHEMIA;

AGED; BLOOD PLATELETS; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; JANUS KINASE 2; MALE; THROMBOCYTHEMIA, ESSENTIAL;

EID: 71449101785     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-009-0284-x     Document Type: Review

References (54)

1. Epstein E, Goedel A (1934) Hemorrhagische Thrombozythamie bei vascularer Schrumpfmilz (Hemorrhagic thrombocythemia with a vascular, sclerotic spleen). Virchows Archiv Pathos Anat Histopathol 293: 233-248.
2. Fanger H, Lj CellaJr, Litchman H (1954) Thrombocythemia: report of three cases and review of literature. N Engl J Med 250: 456-461.
3. Gunz FW (1960) Hemorrhagic thrombocythemia: a critical review. Blood 15: 706-723.
4. Ozer FL, Traux WE, Miesch DC et al (1960) Primary hemorrhagic thrombocythemia. Am J Med 28: 807-823.
5. Dameshek W (1951) Some speculation on the myeloproliferative syndromes. Blood 6: 372-375.
6. Fialkow PJ, Faguet GB, Jacobson RJ et al (1981) Evidence that essential thrombocythemia is a clonal disorder with origin in multipotent stem cell. Blood 58: 916-919.
7. Murphy S, Iland J, Rosenthal D et al (1986) Essential thrombocythemia: clinical and laboratory characteristics at presentation. Semin Hematol 23: 177-192.
8. Vardiman JW, Harris NL, Brunning RD (2002) The world health organization (WHO) classification of the myeloid neoplasms. Blood 14: 2202-2292.
9. Levine RL, Belisle C, Wadleigh M et al (2006) X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood 107: 4139-4141.
10. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
11. Baxter EJ, Scott LM, Campbell PJ et al (2005) Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
12. Kralovics R, Teo SS, Buser AS et al (2005) Altered gene expression in myeloproliferative disorders correlates with activation of signalling by the V617F mutation of Jak2. Blood 106: 3374-3376.
13. James C, Ugo V, Le Couedic JP et al (2005) A unique clonal Jak2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434: 1144-1148.
14. Zhao R, Xing S, Li Z et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280: 22788-22792.
15. Skoda R (2007) The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol 2007: 1-10.
16. Wolanskyj AP, Lasho TL, Schawager SM et al (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131: 208-213.
17. Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on Jak2 V617F mutation status: a prospective study. Lancet 366: 1945-1953.
18. Johansson P (2006) Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemostas 32: 171-173.
19. Randi ML, Putti MC, Scapin M et al (2007) Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 108: 3600-3602.
20. Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110: 1092-1097.
21. Thiele J, Kvasnicka HM (2003) Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82: 148-152.
22. Wilkins BS, Erber WN, Bareford D et al (2007) Bone marrow pathology in essential thrombocythemia: intra-observer reliability and utility for identifying disease subtypes. Blood 111: 60-70.
23. Elliott MA, Tefferi A (2005) Thrombosis and hemorrhage in polycythemia vera and essential thrombocythemia. Br J Haematol 128: 275-290.
24. Cervantes F, Passamonti F, Barosi G (2008) Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 22: 905-914.
25. Fabris F, Randi M, Casonato A et al (1980) Platelet aggregation and thrombopheresis in thrombocythemia. Thromb Haemostas 4: 169.
26. Carobbio A, Finazzi G, Guerini V et al (2007) Leucocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factor and JAK2 mutation status. Blood 109: 2310-2313.
27. Falanga A, Marchetti M, Evangelista V et al (2000) Polymorphonuclear leucocytes activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96: 4261-4266.
28. Carobbio A, Finazzi G, Antonioli E et al (2008) Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 112: 3135-3137.
29. Harrison CN, Campbell RJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high risk essential thrombocythemia. N Engl J Med 353: 33-45.
30. Vannucchi A, AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera and essential thrombocythemia. Blood 110: 840-846.
31. Barbui T, Barosi G, Grossi A et al (2004) Practice guidelines for the therapy of essential thrombocythemia. Haematologica 89: 15-232.
32. Cortelazzo S, Viero P, Finazzi G et al (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8: 556-562.
33. Kiladijan JJ, Cervantes F, Leebeek FWG et al (2008) The impact of Jak2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 111: 4922-4929.
34. Randi ML, Rossi C, Barbone E et al (1994) Superior sagittal sinus thrombosis in 5 patients with essential thrombocythemia: a possible disease variant. Rev Iberoam Tromb Hemostasia 7: 76-78.
35. Federici A, Rand JH, Mannucci PM (2001) Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Hematol J 2: 358-362.
36. Passamonti F, Rumi E, Pungolino E et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117: 755-761.
37. Hasle H (2000) Incidence of essential thrombocythemia in children. Br J Haematol 110: 751.
38. Randi ML, Putti MC, Fabris F (2000) Features of essential thrombocythemia in childhood: study of five children. Br J Haematol 108: 86-89.
39. Dror Y, Zipursky A, Blanchette VS (1999) Essential thrombocythemia in children. J Ped Hematol Oncol 21: 356-363.
40. Randi ML, Putti MC, Pacquola E (2004) Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. Pediatr Blood Cancer 43: 1-4.
41. Randi ML, Putti MC (2004) Essential thrombocythemia in children: is a treatment needed? Exp Opin Pharmacother 5: 1009-1014.
42. Passamonti F, Ml Randi, Rumi E et al (2007) Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the Jak2 (617V>F) mutation. Blood 110: 485-489.
43. Harrison C (2005) Essential thrombocythemia: challenges and evidence-based management. Br J Haematol 130: 153-165.
44. Griesshammer M, Bangerter M, van Vliet HH (1997) Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemostas 23: 371-377.
45. Landolfi R, Marchioli R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350: 114-124.
46. Cortellazo S, Finazzi G, Ruggeri M et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332: 1132-1136.
47. Randi ML, Ruzzon E, Tezza F (2005) Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 16: 181-184.
48. Finazzi G, Ruggeri M, Rodeghiero F et al (2000) Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomised clinical trial. Br J Haematol 110: 577-583.
49. Passamonti F, Malabarba L, Orlandi E et al (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythemia at high risk of thrombosis. Br J Haematol 116: 855-861.
50. Petitt RM, Silverstein MN, Petrone ME (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34: 51-54.
51. Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97: 863-866.
52. Barosi G, Besses C, Birgegard G et al (2007) A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21: 277-280.
53. Barosi G, Birgegard G, Finazzi G et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: results of a ELN consensus conference. Blood [e-pub ahead of print].
54. Apperley JF, Gardembas M, Melo JV et al (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347: 472-480.